SAN FRANCISCO, California. (August 22, 2013) – Kindred Biosciences, Inc. (KindredBio) announced today that it has appointed Stephen Sundlof, DVM, PhD, former Director of Center for Veterinary Medicine at the U.S. Food and Drug Administration, as its Senior Vice President of Regulatory Affairs.
CereKin™ (KIND-001), a novel oral cytokine inhibitor, is expected to be a major step forward in the treatment of dogs with arthritis.
SAN FRANCISCO, California – Kindred Biosciences, Inc. (KindredBio) announced today that it has initiated a pivotal clinical trial for CereKin™ (KIND-001) in dogs with osteoarthritis. The trial is being conducted under a protocol concurrence negotiated with the FDA and, if positive, is expected to lead to the approval of CereKin™ by 2015.
- Kindred Biosciences Announces Second Quarter 2017 Financial ResultsAugust 7, 2017 - 4:02 pm
- Kindred Biosciences Sponsors Veterinary Students to Attend the 2017 American Association of Feline Practitioners MeetingAugust 4, 2017 - 9:04 am
- Kindred Biosciences to Announce Second Quarter 2017 Financial ResultsJuly 24, 2017 - 9:04 am